Wellgistics Health Inc. Evaluates $105M Acquisition of Neuritek Therapeutics

Proposed deal aims to expand Wellgistics' healthcare platform and drug development capabilities.

Mar. 23, 2026 at 9:05pm

Got story updates? Submit your updates here. ›

Wellgistics Health, Inc. has entered into a non-binding letter of intent to evaluate a potential $105 million all-stock acquisition of Neuritek Therapeutics, a neuroscience-focused research organization. The proposed transaction is intended to enhance Wellgistics' existing revenue-generating healthcare platform by expanding capabilities adjacent to its core technology-enabled pharmacy distribution and services business.

Why it matters

The acquisition could strengthen Wellgistics' alignment between drug development and commercialization, enabling earlier engagement with pharmaceutical partners, improving pipeline visibility, and supporting incremental revenue opportunities while enhancing long-term shareholder value through a more integrated and differentiated platform.

The details

The transaction remains subject to due diligence, negotiation of definitive agreements, and other customary closing conditions. Wellgistics is also actively evaluating additional strategic opportunities across healthcare and life sciences as part of its broader growth strategy, which may include other acquisitions, partnerships, or transactions.

  • The letter of intent was signed on March 23, 2026.

The players

Wellgistics Health, Inc.

A rapidly scaling, technology-driven healthcare platform positioned at the center of pharmaceutical distribution and patient access, with an integrated ecosystem spanning wholesale distribution, prescription fulfillment, and AI-powered access solutions.

Neuritek Therapeutics Inc.

A neuroscience-focused research organization that has developed a next-generation bio-mechanism based treatment for Post-Traumatic Stress Disorder (PTSD).

Got photos? Submit your photos here. ›

What’s next

The judge in the case will decide on Tuesday whether or not to allow Walker Reed Quinn out on bail.

The takeaway

This potential acquisition highlights Wellgistics' strategy to expand its healthcare platform and drug development capabilities, which could strengthen its position in the pharmaceutical distribution and patient access markets.